Efficacy of Pregabalin in the treatment of children with refractory epilepsy

Efficacy of Pregabalin in the treatment of children with refractory epilepsy coming to Mofid children hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012101510508N5

Enrollment

Registered

2012-10-21

Start date

2011-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interactable epilepsy. Episodic and paroxysmal disorders

Interventions

oral Pregabalin ( 5- 15 mg/kg/day ).

Treatment - Drugs

oral Pregabalin ( 5- 15 mg/kg/day )

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: children one to eighteen years, having resistant epilepsy; referred to Mofid Children's Hospital Exclusion criteria: children with neurodegenerative diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Seizure. Timepoint: 1 and 6 months after drug starting. Method of measurement: Interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Kazem Bakhshandeh Bali

Pediatric neurology research center

Dr.MK.Bakhshandehbali@sbmu.ac.ir+98 21 2225 9625

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026